戊聚糖聚硫酸钠与间质性膀胱炎患者黄斑病变:系统回顾和荟萃分析。

IF 4 3区 医学 Q1 ANDROLOGY
Jongsoo Lee, Yun Jin Kim, Konghee Lee, Young Kook Kim, Taeho Greg Rhee, Sung Ryul Shim, Jae Heon Kim
{"title":"戊聚糖聚硫酸钠与间质性膀胱炎患者黄斑病变:系统回顾和荟萃分析。","authors":"Jongsoo Lee, Yun Jin Kim, Konghee Lee, Young Kook Kim, Taeho Greg Rhee, Sung Ryul Shim, Jae Heon Kim","doi":"10.5534/wjmh.240295","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC.</p><p><strong>Materials and methods: </strong>PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions.</p><p><strong>Results: </strong>A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' <i>I</i>-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups.</p><p><strong>Conclusions: </strong>This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis.\",\"authors\":\"Jongsoo Lee, Yun Jin Kim, Konghee Lee, Young Kook Kim, Taeho Greg Rhee, Sung Ryul Shim, Jae Heon Kim\",\"doi\":\"10.5534/wjmh.240295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC.</p><p><strong>Materials and methods: </strong>PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions.</p><p><strong>Results: </strong>A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' <i>I</i>-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups.</p><p><strong>Conclusions: </strong>This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.</p>\",\"PeriodicalId\":54261,\"journal\":{\"name\":\"World Journal of Mens Health\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Mens Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5534/wjmh.240295\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Mens Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5534/wjmh.240295","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:戊聚糖聚硫酸钠(PPS)是迄今为止唯一被美国食品和药物管理局批准用于治疗间质性膀胱炎(IC)的药物干预。然而,PPS可能会引起不良事件,黄斑病变,这可能是一个重大挑战。为了确定ic患者pps诱发黄斑病变的风险。材料和方法:系统检索PubMed和Embase至2024年7月。两位作者还独立手动检索了所有相关研究。我们纳入了使用医疗保健索赔大数据或现实世界数据的国家级队列研究,标准如下:(1)诊断为IC的患者;(2)干预措施包括PPS作为积极治疗;(3)比较被指定为非pps干预;(4)关注的主要结局是黄斑病变的风险。进行两两荟萃分析,比较PPS治疗组与IC中使用的对照组。主要结局指标是接受PPS治疗后黄斑病变的风险比(HR)、优势比(OR)和比例报告比(PRR),与非PPS干预相比。结果:进行了全面的文献检索,共纳入6项研究,411,098例患者。IC患者PPS导致黄斑病变的总风险显著(HR, 1.678;95%置信区间[95% CI], 1.066-2.642])。异质性检验产生希金斯i平方统计量,为83.6%。在亚组分析中,随访时间小于5年的患者(HR, 1.285;95% CI, 1.139-1.449)及以上(HR, 1.341;95% CI(1.307-1.375)有统计学意义,表明长期PPS治疗的IC患者发生黄斑病变的可能性高于对照组。结论:这是第一个通过系统回顾和荟萃分析来调查PPS及其与IC患者黄斑病变风险之间关系的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis.

Purpose: Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC.

Materials and methods: PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions.

Results: A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' I-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups.

Conclusions: This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
World Journal of Mens Health
World Journal of Mens Health Medicine-Psychiatry and Mental Health
CiteScore
7.60
自引率
2.10%
发文量
92
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信